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Abstract  Multiparametric  MR  of  the  prostate  provides  an  extremely  accurate  diagnosis  and
offers an  excellent  negative  predictive  value  for  cancers  which  biopsies  struggle  to  detect.
Combined  with  biopsies  they  consolidate  both  positive  and  negative  biopsy  results  and  allow
patients to  be  offered  more  appropriate  treatments  (active  monitoring,  radical  treatment  in  full
knowledge  of  the  topography  of  the  lesions  involved,  or  local  treatment,  etc.).  The  investigation
does not  require  advanced  equipment  and  can  be  carried  out  in  any  MR  centre  although  it  needs
to follow  a  technical  protocol  described  in  the  European  guidelines  (ESUR  2012).  Interpretation
should be  standardized  to  facilitate  communication  of  clear  and  consistent  information  between
practitioners.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
There  is  currently  an  ongoing  debate  on  the  management  of  prostate  cancer,  which  is
believed  to  be  diagnosed  too  early  because  PSA  is  excessively  sensitive  and  to  be  treated
too  invasively.  MR  imaging  of  the  prostate  could  offer  a  solution  to  these  problems  as  it
now  allows  a  very  accurate  distinction  to  be  made  between  ‘‘signiﬁcant’’  cancers  requiring
radical  therapy  and  those  deemed  to  be  ‘‘insigniﬁcant’’  [1,2],  in  which  a  more  conservative
approach  such  as  active  monitoring  can  be  used.  Together  with  new  biomarkers,  it  can  also
be  used  to  assess  how  aggressive  the  tumour  is  [3]. Our  group  has  recently  demonstrated
that  carrying  out  MR  before  the  ﬁrst  series  of  biopsies  improves  the  diagnosis  of  signiﬁcant
prostate  cancers  by  approximately  16%  [4].  Although  this  approach  is  not  yet  ofﬁcially
recommended  pending  a  large  scale  medico-economic  assessment,  new  specialist  centres
are  using  multiparametric  MR  of  the  prostate  and  incorporating  this  routinely  into  their
pre-treatment  and  diagnostic  approach.
∗ Corresponding author.
E-mail address: puech@dicomworks.com (P. Puech).
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Constituent parts of the report44  
Technological  changes  in  prostate  imaging,  some  of  which
apid  or  contentious,  have  suggested  that  the  investigation
s  reserved  for  specialist  centres:  endorectal  coil,  inves-
igation  on  a  3  T  machine,  spectroscopy,  electronic  data
nalysis,  etc.  Technical  differences  have  also  led  to  variabil-
ty  of  reports  to  the  effect  that  MR  has  been  seen  as  complex,
naccessible,  poorly  reproducible  or  clinically  unusable.
In  2010,  Dickinson  et  al.  published  the  ﬁrst  professional
uidelines  describing  the  clinical  indications  and  practical
rocesses  for  carrying  out  ‘‘multiparametric’’  prostate  MR,
roposing  ‘‘rational’’  technical  choices  appropriate  for  the
ndications  deﬁned  by  clinicians  in  everyday  practice,  some
f  which  went  counter  to  the  ofﬁcial  rather  than  old  guide-
ines  [5].  Signiﬁcantly,  and  a  new  feature  inspired  from
he  advances  in  standardizing  breast  imaging,  the  authors
lso  for  the  ﬁrst  time  recommended  international  use  of  a
tandardized  grid  to  describe  the  location  of  lesions  and  a
tandardized  scale  to  provide  a  simple  description  of  the
egree  of  suspicion  of  the  abnormalities  seen.  In  2012,
he  European  Society  for  Uroradiology  (ESUR)  approved  and
o  a  large  extent  reiterated  these  professional  guidelines
nd  proposed  the  ﬁrst  version  of  a  score  entitled  the  ‘‘Pi-
ADS’’  [6]  analogous  to  the  ‘‘Bi-RADS’’  score  used  in  breast
maging.  Since  then,  urologists  and  oncologists  have  had
 practical,  clear  standard.  The  investigation  has  become
tandardized  and  more  accessible  and  its  interpretation,
hich  is  also  being  standardized,  is  better  understood  and
ommunicated.
This  article  provides  a  brief  overview  of  the  technical
eatures  (protocol)  for  multiparametric  prostate  MR  and
escribes  the  process  used  to  obtain  a  standardized,  simple,
ntelligible  report  for  our  referring  physicians.
ow is multiparametric prostate
R performed?
rostate  MR  was  described  as  ‘‘multiparametric’’  at  the
nd  of  the  2000  decade  when  it  became  apparent  that
t  was  not  sufﬁcient  to  settle  for  single  T2  weighted
orphological  imaging  (occasionally  combined  with  spec-
roscopy)  [7].  The  current  ESUR  2012  guidelines  conﬁrm
hat  ‘‘multiparametric’’  MR  (mp-MR)  of  the  prostate  gland
hould  incorporate  at  least  3  different  imaging  techniques,
ach  improving  the  sensitivity  or  speciﬁcity  of  the  diagnosis.
hese  sequences  are  complementary  and  cannot  be  sub-
tituted  as  they  deﬁne  different  histological  appearances
8].
The  ESUR  distinguishes  two  imaging  protocols,  one
o  detect  the  lesions  and  the  other  to  assess  their
xtraprostatic  extension  (staging).  This  requires  high  spa-
ial  resolution  T2  weighted  imaging  (0.3  mm),  which  can  only
e  achieved  with  an  endorectal  coil  on  some  instruments.
or  almost  10  years  however,  the  majority  of  manufacturers
ave  offered  high-resolution  pelvic  coils  (HRPPA),  which  eas-
ly  enable  this  resolution  to  be  achieved  and  therefore  avoid
he  cost  and  discomfort  of  the  endorectal  coil.  Regardless
f  the  technique  used,  the  ESUR  recommends  that  in  both
ituations:
the  patient  should  be  prepared  with  antiperistaltic  treat-
ment  (glucagon);
P
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the  whole  gland  be  covered  in  all  of  the  sequences;
all  of  the  axial  sections  be  imaged  along  a  plane  per-
pendicular  to  the  posterior  aspect  of  the  prostate  rather
than  strictly  in  the  axial  plane.  This  setting  is  facilitated
by  carrying  out  T2  weighted  land-marking  which  clearly
shows  the  hyperintensity  of  the  posterior  peripheral  area
in  contrast  with  the  iso-intense  rectal  wall  on  T2  weighted
imaging;
3  mm  thick  T2  weighted  images  be  taken  in  the  axial  and
sagittal  planes;
diffusion  weighted  imaging  (DWI)  be  carried  out  based  the
T2  weighted  image  with  calculation  of  the  ADC  map  using
at  least  3  diffusion  gradient  values  ‘‘b’’:  0;  100  and  one
value  over  800  (we  recommend  1000  or  1300  on  a  conven-
tional  1.5  T  instrument  and  2000  on  a  modern  1.5  T  or  3  T
instrument);
a  dynamic  contrast  enhanced  image  (DCEMRI)  be  taken
over  5  minutes  with  a  minimum  temporal  resolution  of
15  sec.  The  images  can  be  analyzed  visually  as  can  the
enhancement  curve  if  a  signiﬁcant  lesion  is  present.  The
initial  image  without  contrast  enhancement  can  be  used
to  look  for  hemorrhagic  artifacts;
spectroscopic  imaging  only  be  carried  out  optionally  as  it
adds  10  to  15  minutes  to  the  protocol.
Compared  to  these  speciﬁcations,  we  would  recommend:
that  wherever  possible  and  as  often  as  possible,  the  inves-
tigation  be  performed  before  the  prostate  biopsies  are
taken  (NB:  this  practice  is  not  explicitly  recommended  by
the  French  National  Health  Authority  pending  a  medico-
economic  validation  although  very  signiﬁcantly  improves
the  diagnosis  of  cancer  and  at  the  same  time  enables  a
staging  assessment  to  be  carried  out  without  artifacts  and
in  addition,  without  delay);
that  the  patient  be  optimally  positioned  with  a  coil  cen-
tered  perfectly  on  the  prostate  gland  (which  can  be
checked  on  the  land-marking  image);
that  for  the  T2  weighted  images,  a  rapid  image  is  obtained
in  the  coronal  plane  centered  on  the  median  part  of  the
gland  and  a  high-resolution  coronal  image  to  clearly  visu-
alize  the  conﬂuence  of  the  seminal  vesicle  ducts;
that  in  addition  to  the  ADC  parametric  card,  plain  diffu-
sion  weighted  images  with  a  high  ‘‘b’’  gradient  (b1200
or  b2000)  be  used  to  interpret  the  diffusion  weighted
imaging.  These  offer  different  contrast  to  the  ADC  map
which,  although  it  remains  the  basis  for  visual  interpre-
tation  for  diffusion  weighted  prostate  imaging,  can  fail
to  detect  a  peripheral  lesion  with  a  low  apparent  dif-
fusion  coefﬁcient  in  contact  with  the  periprostatic  fat,
which  is  also  hypo-intense  (as  it  is  saturated).  The  lesion
remains  hyperintense  on  the  plain  sequences  whereas  the
fat  remains  saturated  and  hypo-intense;
that  attempts  be  made  to  achieve  temporal  resolution  of
under  10  sec  for  the  dynamic  image.
tandardizing image interpretationrostatic  mp-MR  should  answer  the  questions  raised  by
he  majority  of  urologists.  These  answers  should  be  easily
ized
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accessible  and  intelligible  depending  on  the  context  in  which
the  report  is  being  read  (consultation,  multidisciplinary
meeting,  etc):  ‘‘Is  a  cancer  present  which  has  been  missed
on  biopsies  or  requires  guided  biopsies?’’,  ‘‘Where  is  the
signiﬁcant  cancer?’’  ‘‘How  many  cancers  are  present  in  the
gland?’’,  ‘‘Where  are  the  risks  for  the  surgical  resection
margins?’’,  ‘‘Can  the  patient  be  offered  curative  treat-
ment?’’,  ‘‘Can  the  patient  be  actively  monitored?’’.  There
are  many  such  questions,  although  they  are  straightfor-
ward  and  require  a  clear  and  structured  answer.  This  was
the  conclusion  of  the  2010  consensus  conference  reiterated
by  the  ESUR  in  2012.  The  MR  information  should  therefore
follow  a  clear  structure:
• dimensions  of  the  gland  and  measurement  of  volume
(which  is  always  useful  to  assess  operability).  Repercus-
sions  of  the  adenoma  on  the  bladder  ﬂoor  (median  lobe);
• description  of  the  overall  appearance  of  the  3  main  zones
of  the  prostate  (the  features  of  which  are  speciﬁc  to  each
one):
◦ appearance  of  the  peripheral  zone.  The  report  should
state  whether  the  gland  is  easy  to  interpret  (obvious
T2  hyperintensity)  or  whether  it  contains  degenerative
changes  (such  as  bleeding)  which  hinder  interpretation
of  the  image,
◦ appearance  of  the  transition  zone:  overall  volume,  sym-
metry  and  the  repercussions  it  is  causing,
◦ appearance  of  the  anterior  ﬁbromuscular  stroma:
development,  whether  or  not  nodular  in  appearance,
whether  or  not  it  enhances  with  contrast;
• Description  of  each  signiﬁcant  lesion,  reporting  for  each:
◦ its  axial  size  in  mm,
◦ its  topography  (following  the  standardized  27-sector
diagram):  the  main  sector  and  the  adjacent  sectors
affected,
◦ a  suspicion  score  from  1  to  5  (Table  1),
◦ another  score,  also  from  1  to  5,  to  assess  extraprostatic
extension  (Table  1).  To  do  this,  the  ESUR  recommends
that  a  scale  from  1  to  5  be  used,  details  of  which  are
available  in  the  original  publication  [6],  although  we
recommend  that  it  be  read  slightly  differently,  to  give  a
score  of  1  if  no  suspected  extension  is  present  (whereas
(
c
v
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Table  1  Standardized  ‘‘Likert’’  scales  from  1  to  5  to  assess  t
MR  and  to  assess  the  risk  that  the  lesion  includes  extraprostat
describe  lesions  but  varies  for  the  description  of  the  extrapros
Score  Signiﬁcance  (brief)  Signiﬁcance  in  the  
the  description  of  t
Score  1  Not  suspicious  Very  unlikely  to  con
clinically  signiﬁcan
Score  2  Relatively  unsuspicious  Unlikely  to  contain
clinically  signiﬁcan
Score  3  Equivocal  It  is  not  possible  to
whether  a  clinically
signiﬁcant  lesion  is
Score  4  Suspicious  Likely  to  contain  a  
signiﬁcant  lesion
Score  5  Highly  suspicious  Highly  likely  to  con
clinically  signiﬁcan report  745
the  ESUR  score  of  1  indicates  that  doubt  is  already
present  about  possible  extension).
The  report  conclusion  should  clearly  state  whether  the
nvestigation  is  interpreted  as  normal  and  if  not,  whether  a
esion  requires  a  guided  sample  to  be  taken  at  the  time  of
iopsy.
ite of the lesions
SUR  proposed  different  ways  of  sub-dividing  the  prostate
nto  8,  16  or  27  sectors.  The  27-sector  subdivision  (Fig.  1),
hich  our  group  has  described  [9],  is  the  only  one  which  dis-
inguishes  cancers  in  the  anterior  ﬁbromuscular  stroma  and
hich  is  also  suitable  for  routine  practice.  It  involves  using
he  12  posterior  sectors  from  which  routine  prostate  biop-
ies  are  taken  and  adding  to  these  the  12  anterior  sectors
epresenting  those  areas  beyond  the  17  mm  of  the  posterior
iopsies  and  3  anterior  median  sectors  where  AFMS  tumours
re  located.  A  total  of  27  sectors  are  described.  In  this
rrangement,  the  12  posterior  sectors  represent  the  most
osterior  17  mm  of  the  gland  (sufﬁx  ‘‘p’’),  from  which  rou-
ine  biopsies  are  taken.  This  means  that  they  may  include
he  posterior  part  of  the  transition  zone.  Conversely,  the
nterior  sectors  (sufﬁx  ‘‘a’’)  may  represent  peripheral  zone
issue,  particularly  in  the  anterior  lateral  horns.  This  dis-
inction  makes  the  27-sector  segmentation  a  ‘‘practical’’
egister  consistent  with  current  biopsy  topography.  The  grid
s  suitable  for  radiologists,  histologists,  urologists  and  onco-
ogists.
mage reading methods
nterpretation  of  a  suspicious  image  varies  depending  on  its
ntraprostatic  location.  We  recommend  that  a  systematic
cheme  be  used  for  reading,  moving  independently  through
he  3  main  compartments  of  the  prostate:  peripheral  zones
PZ),  transition  zone  (TZ)  and  then  the  anterior  ﬁbromus-
ular  stroma  (AFMS),  as  the  appearances  of  each  area  are
ery  different.  A  point-by-point  systematic  analysis  speeds
p  reading  and  avoids  any  part  of  the  gland  being  missed.
he  level  of  suspicion  of  a  lesion  seen  on  multiparametric
ic  extension.  This  is  the  scale  recommended  by  ESUR  to
tatic  lesion.
context  of
he  lesion
Signiﬁcance  in  the  context  of  the
description  of  extraprostatic  extension
of  a  lesion
tain  a
t  lesion
Extension  very  unlikely
 a
t  lesion
Extension  unlikely  (no  direct  or  indirect
signs)
 state
 present
Equivocal  appearances,  unable  to  draw
conclusion  (uncertain,  indirect  or  direct
signs)
clinically Likely  extraprostatic  extension  (direct
sign)
tain  a
t  lesion
Deﬁnite  extraprostatic  extension
(obvious  direct  sign)
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Figure 1. Diagram showing the 27 regions of interest recommended to describe the topography of a suspicious lesion on multiparametric
prostate MR. Three diagrammatic sections of the base, the middle part and the apex are divided into anterior and posterior regions. The
posterior regions (p) are subdivided into medial and lateral lobule areas (n = 12). The anterior regions (a) are symmetrical to the posterior
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segions (n = 15). They begin 17 mm in front of the anterior surface
dentiﬁed representing the anterior ﬁbromuscular stroma. This diag
In  practice,  we  also  recommend  that  the  mp-MR
nvestigation  be  read  with  appropriate  software  which
imultaneously  displays:
a sagittal  landmark  section  for  the  axial  plane;
axial-T2;
high  b  diffusion  weighted  imaging  (eg.  b2000);
ADC  map;
T1 weighted  image  without  enhancement;
dynamic  T1  weighted  image  (DCEMRI)  as  soon  as  possible
after  the  ‘‘T’’  contrast  has  reached  the  gland;
DCEMRI  at  T  +  1.Ideally,  the  software  should  be  able  to  show  you  the
nhancement  curve  for  a  region  of  interest  and  provide
ou  with  semi-quantitative  information.  The  software  must
e  equipped  with  3D  ‘‘pointer’’  function  to  immediately
d
t
i
the gland (the limit of the biopsy core). Three median regions are
can be used for the structured report.
dentify  a  lesion  in  an  image  and  see  its  appearances  imme-
iately  in  the  other  images.
ppearances and scoring the lesion
nterpretation  of  the  ‘‘severity’’  of  a  suspicious  mp-MR
mage  should  be  standardized  in  order  to  improve  inter-  and
ntra-observer  reproducibility  of  reading.  It  should  be  based
n  a  summary  of  the  appearances  seen  in  all  of  the  multipa-
ametric  imaging  sequences,  which  are  not  entirely  similar
epending  on  the  zone  in  which  the  lesion  is  located.  This  is
ummarized  in  Table  2.
Many  groups  have  already  tried  to  classify  lesions  using
ifferent  scales  [10,11]: usually  a  5  point  scale  is  chosen  as
his  offers  an  ‘‘intermediary’’  score  (3/5)  representing  cases
n  which  it  is  not  clearly  possible  to  establish  the  nature  of
he  tissue,  and  leaving  uncertainty  (‘‘equivocal’’  3/5).
Prostate
 cancer:
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Table  2 Appearances  of  prostate  lesions  depending  on  their  zonal  topography.  The  allocation  of  a  standardized  suspicion  score  on  a  1  to  5  scale  for  each  signiﬁcant
image  seen  in  the  gland  should  be  based  on  the  topography  of  the  lesion  (PZ,  TZ  or  AFMS)  and  the  summary  of  the  appearances.  Some  of  these  appearances  are  an
overview  of  the  ﬁndings  from  several  images  in  the  multiparametric  protocol.
Level  of  suspicion Peripheral  zone  (PZ) Transition  zone  (TZ) Anterior  ﬁbromuscular
stroma  (AFMS)
Signs  highly  suspicious
of  a  tumour  lesion
Consistent  ﬁnding  of  an  obvious  T2  weighted
hypo-intensity,  obvious  restricted  diffusion
and  early  contrast  enhancement
Hypo-intense  T2  weighted  nodule  with
convex  borders  clearly  contrasting  with  the
remainder  of  the  peripheral  zone
Consistent  ﬁnding  of  an  obvious  T2  weighted
hypo-intensity,  obvious  restricted  diffusion  and  early
contrast  enhancement
Enhancement  present  even  if
weak+++
Signs  suspicious  of  a
tumour  lesion
Triangular  T2  weighted  hypo-intense  area
with  a  peripheral  base  in  a  PZ  which  is
otherwise  hyperintense  on  T2  weighted
imaging
Profound  restriction  of  diffusion
(<  0,9  mm2/s),  with  no  obvious  nodule
Early  more  intense  contrast  enhancement
contrasting  with  the  rest  of  the  PZ
TZ  nodule  invading  the  AFMS  or  PZ
Poorly  delineated  nodule  ‘‘breaking  the  symmetry’’
of  the  adenoma
Very  homogeneous  appearance  (‘‘pass  through  ﬁlter
paper’’)
Non-circular  nodule
Located  in  the  anterior  half  of  the  TZ  and  in  the
inferior  half  of  the  gland
Located  in  the  superior  rather  than  inferior  half  of
the  TZ
Iso-intense  or  weak  T2  hypo-intense  on  T2  weighted
imaging  (similar  to  the  rectum)
Image  only  visible  on  high  b  plain  diffusion  weighted
imaging  (>  1500)
Iso-intense  on  T2  weighted
imaging  (usually  its  normal
image  is  very  weak  and
similar  to  that  of  the
obturator  or  bladder  muscle)
Non-speciﬁc  signs Posterolateral  rather  than  median  location Very  early  intense  contrast  enhancement  contrasting
with  the  rest  of  the  TZ  (relatively  non-speciﬁc)
Irregular  borders
‘‘Swollen’’  nodular
appearance  of  the  AFMS
(relatively  non-speciﬁc)
Signs  suggestive  of  a
relatively
non-speciﬁc  lesion
Fine  non-nodular  ‘‘band’’  image
abnormality  more  perpendicular  on  the
surface  of  the  prostate
Location  in  the  posterior  half  of  the  TZ
‘‘Circular’’  nodular  appearance
Signs  suggestive  of  a
very  probably  benign
lesion
Strong  symmetrical  hypo-intensity  tending
to  be  lateral  at  both  bases  (this  is  the
central  zone:  the  ‘‘horseshoe’’  sign)
Hypo-intense  areas  present  on  T2
Or  diffusion  weighted  imaging
Very  signiﬁcant  hypo-intensity  on  T2  weighted
imaging  (similar  to  that  of  the  obturator  muscle)
No enhancement
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The  ESUR  recommends  that  a  score  be  allocated  to  each
equence  and  that  a  summated  score  known  as  the  ‘‘Pi-
ADS’’  be  produced  [6,12].  This  is  a  useful  approach,  as
t  requires  a  systematic  analysis  of  the  images.  Portalez
t  al.  used  the  ‘‘somated’’  ESUR  score  on  patients  who
nderwent  a  second  biopsy  series  with  a  threshold  of  ≥  9
ut  of  15,  and  found  a  sensitivity  of  73.5%,  a  negative
redictive  value  of  95.2%  and  accuracy  of  80.4%  [13].  Schim-
oller  et  al.  conﬁrmed  that  inter-observer  reproducibility
sing  this  technique  was  satisfactory  in  a  similar  popula-
ion  (2nd biopsy  series)  [14].  Other  groups  however,  including
osenkrantz  et  al.  have  compared  the  performance  of  the
alculated  ESUR  score  and  a  simple  subjective  score  from
 to  5  in  a  retrospective  population  of  70  patients  before
rostatectomy  and  found  no  signiﬁcant  difference  except
or  the  transition  zone  in  which  paradoxically  the  subjec-
ive  score  was  more  effective  [15].  Pending  a  prospective,
ulticenter  validation  of  the  ESUR  Pi-RADS  score  (the  cal-
ulation  methods  for  which  will  be  described  in  greater
etail)  on  a  population  of  patients  before  their  ﬁrst  biopsy
eries,  we  recommend  that  each  image  be  analysed  sep-
rately  and  that  a  ‘‘personal’’  summary  score  of  1  to  5
e  given  for  each  lesion  (Table  2).  This  summary  score
hould  not  be  a  simple  arithmetic  mean  as  some  lesions
hich  may  be  only  marginally  suspicious  on  one  image  (T2
r  diffusion  weighted,  for  example)  may  be  quite  clearly
uspicious  on  another  (on  a  contrast  enhanced  image,  for
xample).
onclusion
tandardizing  the  MR  imaging  protocol  for  the  prostate
s  an  essential  stage  in  improving  its  accessibility
nd  incorporating  it  into  the  disease  management  pro-
ess.  Modern  MR  instruments  can  use  a  simple  rapid
eproducible  ‘‘multiparametric’’  protocol,  which  performs
xtremely  well  in  locating  signiﬁcant  lesions.  All  of
hese  aspects  beneﬁt  patients.  The  clinical  indications
nd  standard  protocols  are  now  clearly  deﬁned  and
pproved  by  the  learned  societies  on  a  European  level.
adiologists  need  to  work  on  the  reliability  and  repro-
ucibility  of  the  results  reported  by  harmonizing  their
nterpretation  techniques  (training)  and  using  structured
eports  that  facilitate  understanding  and  communicating
esults.
TAKE-HOME  MESSAGES
• Multiparametric  prostate  MR  is  an  essential
investigation  for  optical  management  of  prostate
cancer.
• It  is  a  25-minute  investigation,  which  is
straightforward  to  perform  on  any  instrument
provided  that  certain  technical  guidelines  are
followed  (ESUR  2012)  and  that  the  protocol  is  not
shortened.
• After  simple  training,  it  is  possible  to  produce  high
quality  interpretation  and  a  standardized  report,
which  are  cornerstones  for  the  development  of  this
technique.P.  Puech  et  al.
linical case
uiz 1
linical  details:  sixty-nine  year  old  patient  with  ﬂuctuat-
ng  PSA  levels,  2.4  ng/mL  3  years  ago;  5.7  ng/mL  1  year  ago
nd  3.8  ng/mL  recently.  A  ﬁrst  biopsy  series  was  performed
n  another  centre  not  guided  by  MR  prebiopsies.  A  1-mm
icrofocus  was  found,  Gleason  3  +  3  on  biopsy  ‘‘5’’  (Fig.  2).
uestions
.  Where  was  the  patient’s  cancer  located?  (one  answer
only)
a.  On  the  right.
b.  At  the  left  apex.
c.  At  the  right  base.
d.  Impossible  to  answer  as  the  urologist’s  biopsy  sites
are  not  known.
. Why  was  this  patient  not  treated  6  months  ago?  (there
are  several  correct  answers)
a.  It  is  possible  he  did  not  wish  to  be  treated.
b.  Because  the  cancer  is  not  signiﬁcant  and  active  mon-
itoring  was  appropriate.
c.  Because  the  cancer  was  located  in  an  area  which  is
inaccessible  to  surgery.
d.  Because  a  cancer  is  not  treated  without  second  his-
tological  proof.
.  Why  is  the  image  poorly  visible  on  the  ADC  map  whereas  it
is  clearly  visible  on  the  T1  weighted  subtraction  dynamic
image?  (several  answers  are  correct)
a.  Because  it  is  a  1.5  T  investigation.
b.  Because  a  second  endorectal  coil  was  not  used.
c.  Because  it  was  performed  using  a  b  gradient  of  under
1000.
d.  Because  the  ‘‘plane’’  diffusion  weighted  image  also
needs  to  be  examined.
e.  Because  it  may  be  too  small  in  size.
f.  Because  the  perfusion  imaging  shows  lesions  which
diffusion  weighted  imaging  cannot  show  (and  vice
versa).
nswers
.  Answer  D:  urologists  generally  take  biopsies  using  a  12-
biopsy  plan  although  in  practice  the  order  in  which  the
histology  cartridges  are  ﬁlled  varies.  Encourage  your
teams  to  use  the  27-sector  plan  recommended  by  ESUR
to  send  the  results  to  histology.
.  Answers:  A,  B.  This  patient  was  eligible  for  active  moni-
toring.  In  this  case  it  is  an  insigniﬁcant  cancer  when  only
the  histological  deﬁnition  is  used:  less  than  3  biopsies
with  less  than  3  mm  of  cancer  in  each  and  no  grade  4;  the
criterion  ‘‘MR  shows  no  signiﬁcant  lesion’’  can  be  incor-
porated  in  this  in  order  to  avoid  missing  lesions  which  are
not  diagnosed  from  biopsies.
.  Answers  D,  E,  F.
a)  False.  Investigations  performed  on  a  1.5  T  instrumentproduce  an  identical  or  better  yield  and  accuracy  than
those  performed  in  a  3  T  instrument  in  most  of  the
comparative  studies.  Diffusion  weighted  images  often
contains  far  more  artifacts  at  3  T  than  at  1.5  T.
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4Figure 2. A 1-mm microfocus was found on a ﬁrst biopsy series. G
3 + 4 = 7 left basal lesion.
b)  False.  The  endorectal  coil  has  not  been  shown  to
improve  detection  of  intraprostatic  lesions.
c)  False.  Diffusion  weighted  imaging  using  3  different
‘‘b’’  diffusion  gradients  is  recommended,  the  high-
est  of  which  is  over  800,  although  excellent  images
can  be  obtained  with  a  lower  gradient  (in  this  case
b  =  600).
d)  True.  If  a  lesion  is  in  contact  with  the  fatty  prostate
surface  (saturated)  its  ADC  hypo-intensity  may  be
undetectable.  This  disadvantage  is  overcome  when
the  plain  (high  b  value)  diffusion  weighted  images  are
read.
e)  True.  The  threshold  for  detection  of  prostatic  lesions
is  in  the  region  of  7  mm  in  the  peripheral  zone  and
10  mm  in  the  transition  zone.
f)  True.  The  ‘‘multiparametric’’  MR  ‘‘functional’’
images  are  complementary  and  synergistic.
Final comments on the case
This  patient  had  a  Gleason  3  +  4  +  7  (aggressive)  adenocarci-
noma  on  3  of  the  4-guided  biopsies  (5,  5  and  6  mm)  and  on
two  routine  biopsies  from  the  left  apex  (2  mm  and  4  mm).
He  was  treated  by  focused  ultrasound  because  of  his  age.
This  case  illustrates  the  beneﬁts  of  MR  in  correctly  classify-
ing  patients  as  suitable  or  unsuitable  for  active  monitoring
and  the  merits  of  ‘‘multiparametric’’  image  reading.Quiz 2
Clinical  details:  ﬁfty-seven-year-old  patient  with  a  raised
PSA  of  4.25  ng/mL  and  a  ratio  of  26%  1  year  ago  comparedon 3 + 3 on biopsy ‘‘5’’. Prostatectomy conﬁrmed a 12-mm Gleason
o  3.57  ng/mL  4  years  ago.  Assessment  before  a  ﬁrst  series
f  biopsies.  The  patient  has  a  suspicious  MR  (Fig.  3).
uestions
.  In  which  standardized  sector  would  you  place  this  image?
(one  answer  only)
a)  z02a
b)  z08a
c)  z12c
d)  z08p
e)  z09p
.  What  score  would  you  give  this  image?  (one  answer  only)
a)  1/5  as  it  is  not  suspicious  on  diffusion  weighted  imag-
ing
b)  2/5  as  it  is  not  suspicious  on  T2  weighted  imaging
c)  3/5  as  it  is  equivocal  in  all  of  the  images
d)  4/5
e)  5/5
.  How  would  you  score  the  extraprostatic  extension?  (one
answer  is  correct)
a)  1/5  or  2/5
b)  2/5  or  3/5
c)  3/5  or  4/5
d)  4/5  or  5/5
e)  I  cannot  score  it  as  there  is  no  endorectal  coil
.  How  would  you  score  the  hypo-intense  image  located  in
the  right  peripheral  zone?  (one  answer  is  correct)
a)  1/5
b)  2/5  or  3/5
c)  4/5  or  5/5
750  P.  Puech  et  al.
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iigure 3. Positive routine biopsy at the right base: 3 mm Glea
leason 6, 10 mm in size at the right base, pT2cN × R0.
nswers
.  Answer:  B.  Comments:
)  False:  right  anterior  lateral  base
)  True:  left  basal  anterior  horn.  From  the  sagittal  image
the  tightest  margin  can  be  seen  to  be  at  the  base.  The
images  in  the  peripheral  zone  and  not  therefore  zone
z07a
c)  False
)  False:  the  image  is  anterior  although  it  is  in  the
‘‘peripheral’’  zone
)  False
.  Answer:  E.  Comments:
a) False.  The  image  is  very  suspicious  as  it  has  typ-
ical  appearances  of  nodular  hypo-intensity  on  the
T2  weighted  image  in  a  peripheral  zone,  which
is  overall  T2  hyperintense  +  hypo-intense  on  the
ADC  map  +  early  intense  enhancement  +  consistency
between  signs  +  posterolateral  topography  in  PZ
b)  False:  same  comment
c)  False:  same  comment
d)  False:  same  comment.  The  lesion  here  is  more  than
‘‘suspicious’’  as  it  has  all  the  signs  of  disease
e)  True:  same  comment
.  Answer:  A.  Comments:
a) True.  Although  the  lesion  was  in  contact  with  the
surface  of  the  prostate  there  are  no  direct  signs  of
extension  beyond  this
b)  False:  idem
c)  False:  idem
d)  False:  idem
e)  False:  the  endorectal  coil  has  not  been  shown
to  improve  detection  of  extraprostatic  extension
D
T
c + 3 = 6. Prostatectomy conﬁrmed an inﬁltrating focus of disease,
compared  to  a  high-resolution  pelvic  coil,  particularly
for  anterior  lesions
.  Answer:  B.  Comments:
a) False:  the  right  basal  image  is  not  nodular  but  it  is
clearly  distinct  from  the  rest  of  the  parenchyma  on
T2  weighted  imaging  (3/5).  It  is  almost  invisible  on
the  diffusion  weighted  image  (1/5),  and  exhibits  very
weak  enhancement  on  perfusion  imaging  (2/5).  Over-
all  it  is  relatively  non-suspicious
b)  True:  idem
c)  False:  idem
inal comments on the case
he  biopsies  from  this  patient  showed  1  positive  routine
iopsy  at  the  left  base:  2  mm  Gleason  3  +  3  =  6,  1  positive  rou-
ine  biopsy  at  the  right  base  (Fig.  3):  3  mm  Gleason  3  +  3  =  6,
 positive  guided  biopsies  from  the  nodule  at  the  left  base
Fig.  2):  3  and  4  mm  Gleason  3  +  3  =  6.  Prostatectomy  con-
rmed  a  12-mm  Gleason  3  +  4  =  7 left  basal  lesion  (Fig.  2)
nd  an  inﬁltrating  focus  of  disease,  Gleason  6,  10  mm  in  size
t  the  right  base,  pT2cN  ×  R0.  This  case  illustrates  the  ben-
ﬁt  of  MR  before  prostate  biopsies.  Without  MR  the  patient
ould  have  been  placed  on  active  monitoring  despite  hav-
ng  a  signiﬁcant  cancer.  It  also  shows  that  diffusion  weighted
maging  can  fail,  particularly  with  low-grade  lesions.isclosure of interest
he  authors  declare  that  they  have  no  conﬂicts  of  interest
oncerning  this  article.
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